Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × BEBT-908 × Clear all
NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med Inc

Phase 3 Recruiting
416 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡